One aspect of the present disclosure relates to a method for controlling levels of perceived intensity of a sensory stimulus. The method includes configuring a stimulation signal with an activation charge rate (ACR) based on a predefined level of intensity by a subject during an action. The ACR is based on a strength of pulses in the stimulation signal parameter and a frequency of pulses in the stimulation signal parameter. The stimulation signal can be applied to neural tissue of a subject during the action. Based on the stimulation signal, the subject can be induced to perceive the predefined level of intensity during the action.

A shield member is placed within a polymer flexible carrier in between a manipulation member used to aid implant of a nerve cuff and the nerve to avoid touching the nerve surface with the manipulation member because the texture or material of the flexible member typically causes more foreign body reaction or other biologic reaction from the nerve and surrounding tissues than the polymer of the flexible carrier itself.

Restless Leg Syndrome (RLS) or Periodic Limb Movement Disorder (PLMD) can be treated using high frequency (HF) electrostimulation. This can include selecting or receiving a subject presenting with RLS or PLMD. At least one electrostimulation electrode can be located at a location associated with at least one of, or at least one branch of, a sural nerve, a peroneal nerve, or a femoral nerve. HF electrostimulation can be delivered to the subject, which can include delivering subsensory, subthreshold, AC electrostimulation at a frequency that exceeds 500 Hz and is less than 15,000 Hz to the location to help reduce or alleviate the one or more symptoms associated with RLS or PLMD. A charge-balanced controlled-current HF electrostimulation waveform can be used.

Methods and apparatuses for setting a therapeutic dose of a neuromodulator implanted into a patient are described. The therapeutic dose typically includes a therapeutic dose duration including a ramp-up time to reach a peak modulation voltage and a sustained peak modulation time during which the voltage is sustained at the peak modulation voltage. The methods and apparatuses described herein may use a testing ramp to identify a peak modulation voltage that is patient-specific and provides a maximized therapeutic effect while remaining comfortably tolerable by the patient during the application of energy by the neuromodulator.

Modulation of neural signaling of a pancreas-related sympathetic nerve is capable of improving glycaemic control by inhibiting T cell activation or migration to the pancreas, and hence providing a way of treating or preventing type 1 diabetes.

An electrode lead comprises a lead body, connector contacts affixed to the proximal end of the lead body, and a cuff body affixed to the distal end of the lead body. The cuff body is pre-shaped to transition from an unfurled state to a furled state, wherein the cuff body, when in the furled state has an inner surface for contacting a nerve and an overlapping inner cuff region and an outer cuff region. The electrode lead further comprise electrode contacts circumferentially disposed along the cuff body when in the furled state, such that at least one of the electrode contacts is located on the inner surface of the cuff body, and at least another of the electrode contacts is located between the overlapping inner and outer cuff regions. The electrode lead further comprises electrical conductors extending through the lead body respectively between the connector contacts and the electrode contacts.

The present invention provides an implantable electrode device, a medical device/system thereof, and a diagnostic and/or therapeutic method using the medical device/system. The implantable electrode device includes a flexible non-conductive flap, one or more electrodes integrated with the flap, and one or more wires embedded within the flap and connected to the one or more electrodes. The invention exhibits numerous technical merits such as stable fixation of the electrode to a biological target in a patient.

The disclosure provides systems and methods for automatically titrating an electrical pulse amplitude for a patient-implanted VNS stimulator. One or more external sensors (e.g., EEG, EKG, EMG, auditory sensors, inertial motion sensors, etc.) can be applied to the patient to generate data relevant to an acceptable amplitude of the electrical pulse for a given cathode in a multi-cathode cuff. In one embodiment, the device may include a controller on the implanted VNS stimulator that receives data, e.g., using a wireless connection, from the external sensors and titrates upward the amplitude until an acceptable amplitude is determine that provides efficacy with minimal, if any, side effects.

A lead body is operable to be implanted proximate a target nerve tissue of a patient. A sensing electrode is configured to sense biopotentials over a first partial circumference of the lead body. A stimulation electrode is configured to deliver stimulation energy over a second partial circumference of the lead body. A signal generator is electrically coupled to the stimulation electrode and a sensing circuit is coupled to the sensing electrode. A processor is operable to apply a stimulation signal to the stimulation electrode via the signal generator and, via the sensing circuit, sense an evoked response to the stimulation signal that propagates along a neural pathway.

The present disclosure discusses a nerve cuff that includes a thin-film elastic mesh with an integrated array of electrodes. The nerve cuff can wrap around a human carotid artery or other tissue to stimulate the autonomic nervous system. The nerve cuff can include a housing that secures the mesh to the carotid artery or other tissue.